Last reviewed · How we verify
NCT04262869
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Phase 2 trial testing Carboplatin in Lung Non-Small Cell Carcinoma. Withdrawn.
18 October 2021
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 27 March 2020 |
| Primary completion | 18 October 2021 |
| Estimated completion | 18 October 2021 |
Drugs / interventions tested
- Carboplatin
- Durvalumab — full drug profile →
- Paclitaxel — full drug profile →
- Pemetrexed — full drug profile →
Conditions studied
- Lung Non-Small Cell Carcinoma — all drugs for Lung Non-Small Cell Carcinoma →
- Stage IIIB Lung Cancer AJCC v8 — all drugs for Stage IIIB Lung Cancer AJCC v8 →
- Stage IV Lung Cancer AJCC v8 — all drugs for Stage IV Lung Cancer AJCC v8 →
- Stage IVA Lung Cancer AJCC v8 — all drugs for Stage IVA Lung Cancer AJCC v8 →
Sponsor
Emory University
Who can join
18 and older, any sex, with Lung Non-Small Cell Carcinoma or Stage IIIB Lung Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well platinum-based chemotherapy works when given together with durvalumab in treating patients with stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to find out if the combination of chemotherapy in combination with the immune therapy drug durvalumab would be efficacious and have an acceptable toxicity profile in patients with advanced non-small cell lung cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments.
Czarnomysy R, Radomska D, Szewczyk OK, Roszczenko P, et al · · 2021 · cited 47× · PMID 34361037 · DOI 10.3390/ijms22158271 -
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis.
Facchinetti F, Di Maio M, Perrone F, Tiseo M. · · 2021 · cited 30× · PMID 34295688 · DOI 10.21037/tlcr-21-15
Verify or expand the search:
- PubMed search for NCT04262869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Carboplatin
Trials testing the same drug.
- NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
Other recruiting trials for Lung Non-Small Cell Carcinoma
Currently open trials in the same condition.
- NCT07216404 — Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT07339254 — Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study · recruiting
- NCT06983899 — Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell · NA · recruiting
- NCT07186699 — Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD · recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04262869 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 27 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04262869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing